Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Retained Earnings (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Retained Earnings for 8 consecutive years, with -$548.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 17.99% to -$548.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$548.3 million, a 17.99% decrease, with the full-year FY2024 number at -$482.5 million, up 1.46% from a year prior.
  • Retained Earnings was -$548.3 million for Q3 2025 at Precision Biosciences, down from -$526.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$283.1 million in Q2 2021 to a low of -$548.3 million in Q3 2025.
  • A 5-year average of -$425.5 million and a median of -$453.4 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 49.46% in 2021, then rose 3.65% in 2024.
  • Precision Biosciences' Retained Earnings stood at -$316.7 million in 2021, then crashed by 35.25% to -$428.3 million in 2022, then fell by 14.32% to -$489.6 million in 2023, then grew by 1.46% to -$482.5 million in 2024, then dropped by 13.65% to -$548.3 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Retained Earnings are -$548.3 million (Q3 2025), -$526.5 million (Q2 2025), and -$503.0 million (Q1 2025).